Gonzalez-Ortiz, Ailema
Clase, Catherine M.
Bosi, Alessandro
Fu, Edouard L.
Pérez-Guillé, Beatriz E.
Faucon, Anne-Laure
Evans, Marie
Zoccali, Carmine
Carrero, Juan-Jesús http://orcid.org/0000-0003-4763-2024
Funding for this research was provided by:
Vetenskapsrådet
Karolinska Institute
Article History
Received: 5 September 2023
Accepted: 29 November 2023
First Online: 18 January 2024
Declarations
:
: JJC has conducted studies for which Karolinska Institutet has received support from AstraZeneca (manufacturer of sodium zirconium cyclosilicate), ViforPharma (manufacturer of patiromer), Novonordisk, Astellas, MSD, GSK, Boehringer Ingelheim and Amgen; He also reports receiving lecture fees from Baxter, Fresenius Kabi, AstraZeneca, Astellas, GSK and Abbott; and participation in advisory boards for Astrazeneca, Nestle and Bayer; ME reports payment for lectures (Astellas pharma, Vifor pharma, Astra Zeneca, Baxter healthcare and Fresenius Medical care) and attendance in advisory boards (Astellas pharma, Vifor pharma, Astra Zeneca). The rest of the authors have no conflict of interest to report.
: The regional ethical review board in Stockholm approved the study.
: The present study complies with the guidelines for human studies.
: Informed consent was not deemed necessary because all data were deidentified at the Swedish Board of Health and Welfare.